Key Takeaways
- Kenvue reports $3.96 billion in Kenvue Q2 sales, narrowly missing analyst estimates.
- Skin Health & Beauty sales rise 5.1%, led by skin and hair care.
- Tariffs, inflation and currency pressures squeeze Kenvue’s margins despite higher profits.
Kenvue reports $3.96 billion in second-quarter sales as tariffs, inflation and currency costs pressure margins, while its beauty division posts stronger sales and profits.
Kenvue Misses Sales Estimate As Costs Rise
Kenvue Q2 sales rose 3% from a year earlier but narrowly missed analysts’ $3.97 billion estimate, according to company results reported Aug. 6. Net income increased to $456 million from $420 million.
The consumer health company says inflation, tariffs and unfavorable foreign exchange rates offset savings from productivity efforts. Adjusted gross margin fell to 60.2% from 60.9% a year earlier, while adjusted operating margin declined to 22.1% from 22.7%.
Kenvue CEO Kirk Perry said the company is continuing to improve operations despite challenging economic conditions. “Our transformation is firmly on track,” Perry said, according to The Wall Street Journal.
The latest Kenvue Q2 sales results come as the company works toward its planned combination with Kimberly-Clark, which agreed to acquire the consumer health company in a deal valued at more than $40 billion. The transaction is expected to close in the fourth quarter of 2026, subject to remaining conditions.
Skin Health And Beauty Leads Growth
Kenvue’s Skin Health & Beauty division delivered the company’s strongest growth during the quarter, with sales reaching $1.11 billion, up 5.1% from the same period last year.
Organic sales in the division increased 3.7%, supported by growth in skin and hair care. The company points to strong e-commerce activity and new products, including OGX Pro Growth & Peptide and Neutrogena Ultra Sheer Sun.
Neutrogena also continued to gain ground in the United States. Household penetration increased for the third consecutive quarter as the brand increased investment and commercial activity.
Adjusted operating income in Skin Health & Beauty rose nearly 25%, from $149 million to $186 million. The improvement helped offset broader pressure on Kenvue’s margins.
Kenvue Prepares For Kimberly-Clark Deal
Kenvue’s latest results mark an improvement from 2025, when the company faced weaker sales and profitability. Its current performance comes as management focuses on operational improvements ahead of the planned acquisition.
Reuters reported that Kenvue’s adjusted earnings per share were 31 cents, below the 32-cent analyst estimate. The company’s organic sales increased 1.6% overall, supported by higher prices and volume growth.
Kenvue is not providing forward-looking guidance because of the pending Kimberly-Clark transaction. The companies’ shareholders approved the deal in January, and Kenvue said the transaction is expected to close in the second half of 2026, subject to regulatory approvals and other customary conditions.
Overall, Kenvue Q2 sales show the company balancing two priorities: improving growth in major consumer brands while managing higher costs and completing its transition into Kimberly-Clark. The company’s latest Kenvue Q2 sales figures provide a snapshot of its performance as it prepares for the next stage of the business.
Visit CIO Women Magazine For The Most Recent Information.
